Our Pipeline

Unique Pathways with Targets That Matter

Teon’s rich pipeline targets unexploited metabolic pathways backed by well-validated science and a track record developing first- and best-in-class GPCR-directed therapies.

Our highly accomplished scientific team methodically develops and evaluates candidates, leveraging decades of expertise in tumor metabolism, cell signaling and GPCR therapeutic design. Our first candidate, TT-702, was developed concept-to-clinic in only 18 months. The momentum continues, solving for unmet needs in cancer care as we advance additional pipeline candidates.

Candidate
Target
Best or First-in-Class
Indications
Discovery
Pre-Clinical
IND
Phase 1
CB2 Receptor Antagonist (Checkpoint Inhibitor)
NSCLC, RCC, Ovarian
A2B Receptor Antagonist
mCRPC, TNBC, MSI/MMR
TT-373
MCT4 Lactate Transport Inhibitor
Undisclosed
TT-X
CD73 Enzyme Inhibitor
Undisclosed

UDT = Undisclosed Target

Candidate: TT-816

Target
Best or First-in-Class
Indications
CB2 Receptor Antagonist (Checkpoint Inhibitor)
NSCLC, RCC, Ovarian
Discovery
Pre-Clinical
IND
Phase 1

Candidate: TT-702

Target
Best or First-in-Class
Indications
A2B Receptor Antagonist
mCRPC, TNBC, MSI/MMR
Discovery
Pre-Clinical
IND
Phase 1

Candidate: TT-373

Target
Best or First-in-Class
Indications
MCT4 Lactate Transport Inhibitor
Undisclosed
Discovery
Pre-Clinical
IND
Phase 1

Candidate: TT-X

Target
Best or First-in-Class
Indications
CD73 Enzyme Inhibitor
Undisclosed
Discovery
Pre-Clinical
IND
Phase 1/2

UDT = Undisclosed Target

Our clinical-stage candidates

TT-816

First-in-class small molecule cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor being evaluated for the treatment of a broad range of solid tumors including NSCLC, RCC and Ovarian.

TT-702

First-in-class, oral, adenosine A2B receptor antagonist in Phase 1/2 clinical trial for the treatment of patients with a range of difficult-to-treat cancers including mCRPC, TNBC and MSI/MMR.

mCRPC = Metastatic Castration-Resistant Prostate Cancer
TNBC = Triple Negative Breast Cancer
MSI = Microsatellite instability
MMR = DNA mismatch repair
RCC = Renal Cell Carcinoma
NSCLC = Non-Small Cell Lung Cancer

Partnerships

In addition to our own internal work, we are pursuing partnerships to help maximize the value of our innovations and advance medicines that make a difference in the lives of patients. We recognize the tremendous need, and value strategic partnerships in moving cancer care forward. To learn more about partnership opportunities, please contact our team.